Physician profile
Maria Padilla
NPI 1285652024
$83,006.72
in general payments reported to CMS, 2019-2025
15 companies · $16K in 2025
The $16K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $13K · 2021: $18K · 2022: $6,115 · 2023: $139 · 2024: $7,852 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $3,233 · Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,550.00 |
| Travel and Lodging | $3,233.42 |
| Food and Beverage | $1,233.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42,254.09 | 2019-2025 | Ofev |
| Genentech USA, INC. | $21,233.33 | 2019-2022 | |
| United Therapeutics Corporation | $15,555.53 | 2021-2025 | Tyvaso |
| Genentech, INC. | $2,000.00 | 2020 | |
| Boehringer Ingelheim International Gmbh | $893.74 | 2022 | |
| Nippon Boehringer Ingelheim Co., LTD. | $800.00 | 2019 | |
| Electromed, INC. | $240.50 | 2023-2024 | Smartvest |
| Insmed, INC. | $29.53 | 2025 | Arikayce |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.